Aneurysmal Subarachnoid Hemorrhage Clinical Trial
— LongTEAMOfficial title:
Long-term Prognosis of Emergency Aneurysmal Subarachnoid Hemorrhage: an MDT- Based Multicenter Cohort Study
NCT number | NCT04785976 |
Other study ID # | KY 2020-11-26 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2012 |
Est. completion date | April 1, 2032 |
Rupture of intracranial aneurysms can lead to extensive subarachnoid hemorrhage (SAH), a potentially fatal neurological emergency with mortality rates ranging from 8 to 67%. At present, surgical clipping (SC) and endovascular coiling (EC) are two main treatments for aneurysmal subarachnoid hemorrhage (aSAH), in recent years, the improvements in surgical equipment and techniques have already greatly improved the postoperative safety of patients. However, considering individual differences between patients, some still at risk due to possible complications during hospitalization or after discharge from the hospital, it will no doubt generate a large healthcare burden. This prospective, observational clinical trial (LongTEAM) is to improve the diagnosis and treatment effect and efficiency in this field, reducing mortality, medical costs, and medical burden, while opening up new avenues for interdisciplinary clinical practice and scientific research exploration.
Status | Recruiting |
Enrollment | 5000 |
Est. completion date | April 1, 2032 |
Est. primary completion date | March 1, 2032 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - All patients admitted to the emergency department of the investigator with aneurysmal subarachnoid hemorrhage are included in their prospective registry. Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
China | Beijing Tiantan Hospital | Beijing | Beijing |
China | The First People's Hospital of Neijiang | Neijiang | Sichuan |
Lead Sponsor | Collaborator |
---|---|
Beijing Tiantan Hospital | Peking University International Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Unfavorable neurological outcome (mRS>2) | Number of patients experiencing a unfavorable neurological outcome at discharge, defined as a modified Rankin Scale (mRS) score of >2. | 10 days after the procedure | |
Primary | Unfavorable neurological outcome (mRS>2) | Number of patients experiencing a unfavorable neurological outcome at 3 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. | 3 months | |
Primary | Unfavorable neurological outcome (mRS>2) | Number of patients experiencing a unfavorable neurological outcome at 6 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. | 6 months | |
Primary | Unfavorable neurological outcome (mRS>2) | Number of patients experiencing a unfavorable neurological outcome at 12 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. | 12 months | |
Primary | Unfavorable neurological outcome (mRS>2) | Number of patients experiencing a unfavorable neurological outcome at 24 months post-treatment, defined as a modified Rankin Scale (mRS) score of >2. | 24 months | |
Secondary | Cognitive deficits | Number of patients experiencing a unfavorable neurological outcome at discharge,defined as changes in thinking, emotion, will and behavior. | 10 days after the procedure | |
Secondary | Cognitive deficits | Number of patients experiencing a unfavorable neurological outcome at 3 months, defined as changes in thinking, emotion, will and behavior. | 3 months | |
Secondary | Cognitive deficits | Number of patients experiencing a unfavorable neurological outcome at 6 months, defined as changes in thinking, emotion, will and behavior. | 6 months | |
Secondary | Cognitive deficits | Number of patients experiencing a unfavorable neurological outcome at 12 months, defined as changes in thinking, emotion, will and behavior. | 12 months | |
Secondary | Cognitive deficits | Number of patients experiencing a unfavorable neurological outcome at 24 months, defined as changes in thinking, emotion, will and behavior. | 24 months | |
Secondary | Major adverse cardiac or cerebrovascular events | Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at discharge. | 10 days after the procedure | |
Secondary | Major adverse cardiac or cerebrovascular events | Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 3 months. | 3 months | |
Secondary | Major adverse cardiac or cerebrovascular events | Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 6 months. | 6 months | |
Secondary | Major adverse cardiac or cerebrovascular events | Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 12 months. | 12 months | |
Secondary | Major adverse cardiac or cerebrovascular events | Number of patients experiencing an event including all-cause death, non-fatal cerebrovascular event, non-fatal any myocardial infarction and revascularization at 24 months. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03209830 -
Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT05131295 -
Dapsone Use in Patients With Aneurysmal Subarachnoid Hemorrhage.
|
Phase 3 | |
Recruiting |
NCT04583163 -
Variability in Transcranial Doppler Technique in Neuro-Critical Care Patients
|
||
Not yet recruiting |
NCT03271697 -
Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage
|
Phase 2/Phase 3 | |
Recruiting |
NCT01098890 -
Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage
|
Phase 2 | |
Completed |
NCT00692744 -
Quality of Life in Elderly After Aneurysmal Subarachnoid Hemorrhage (SAH)
|
N/A | |
Active, not recruiting |
NCT05738083 -
Prediction Models for Complications, Disability, and Death in Patients With Aneurysmal Subarachnoid Hemorrhage
|
||
Completed |
NCT03754335 -
SubArachnoid Hemorrhage HEadache Treated by Lumbar Puncture
|
N/A | |
Completed |
NCT06076590 -
Impact of Multiple Electrolytes Injection Ⅱ and Saline on Hyperchloremia in Patients With Aneurysmal Subarachnoid Hemorrhage:a Pilot Study
|
Phase 4 | |
Recruiting |
NCT04548401 -
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage
|
||
Terminated |
NCT04148105 -
Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)
|
Phase 4 | |
Recruiting |
NCT06329635 -
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
|
N/A | |
Recruiting |
NCT02129413 -
Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm
|
N/A | |
Terminated |
NCT00487461 -
Use of Simvastatin for the Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT06288659 -
aSAH Treatment Based on Intraventricular ICP Monitoring: A Prospective, Multicenter, Randomized and Controlled Trial
|
N/A | |
Recruiting |
NCT05974111 -
COAgulation Disorders in Ischaemic and Haemorrhagic Stroke
|
||
Recruiting |
NCT03706768 -
Degradation of the Glycocalyx in Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Recruiting |
NCT06284642 -
Early Lumbar Drainage Combined With Intrathecal Urokinase Injection for Treatment of Severe Aneurysmal SAH (LD-ITUK)
|
Phase 4 | |
Recruiting |
NCT01773200 -
Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage
|
N/A | |
Completed |
NCT02026596 -
SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage
|
N/A |